The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers.
 
Kwang-Yu Chang
No Relationships to Disclose
 
Nai-Jung Chiang
No Relationships to Disclose
 
Chia-Jui Yen
No Relationships to Disclose
 
Shang-Yin Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis; Roche; Sanofi
 
Shang-Hung Chen
No Relationships to Disclose
 
Amanda Johnston
Employment - Polaris
Stock and Other Ownership Interests - Polaris
Travel, Accommodations, Expenses - Polaris
 
John S. Bomalaski
Employment - Polaris
Leadership - Polaris
Stock and Other Ownership Interests - Polaris
Patents, Royalties, Other Intellectual Property - Patents
Travel, Accommodations, Expenses - Polaris
 
Bor-Wen Wu
Employment - Polaris
Leadership - Polaris
Stock and Other Ownership Interests - Polaris
Patents, Royalties, Other Intellectual Property - Polaris
 
Li-Tzong Chen
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm
Research Funding - Celgene (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); SynCoreBio (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan